LitAlert ~~ GeneLit.com

    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
    • [New advances in targeted therapy for breast cancer].
    • Zhao J, Wu N, Zhang SC, Zhao ZW, Li LJ, Liu JT.
    • Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. Chinese. doi: 10.3760/cma.j.cn112152-112152-20190919-00614.
    • Review, [Article in Chinese]
  • LitAlert ~~ GeneLit.com

    • Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 1.

    Drug Approval: FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (U.S. Food & Drug Administration)

    • Olaparib Makes OS Gains in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2020 May 29. doi: 10.1158/2159-8290.CD-NB2020-048. Epub ahead of print.
    • News
    • Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
    • Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N.
    • Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4.
    • Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F.
    • Int J Mol Sci. 2020 May 27;21(11):E3805. doi: 10.3390/ijms21113805.
    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 May 21:S1879-8500(20)30099-0. doi: 10.1016/j.prro.2020.04.003. Epub ahead of print.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

  • LitAlert ~~ GeneLit.com

    • Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
    • Lee JS, Yost SE, Yuan Y.
    • Cancers (Basel). 2020 May 29;12(6):E1404. doi: 10.3390/cancers12061404.
    • Establishing a framework for the clinical translation of germline findings in precision oncology.
    • Dixon K, Young S, Shen Y, Thibodeau ML, Fok A, Pleasance E, Zhao E, Jones M, Aubert G, Armstrong L, Virani A, Regier D, Gelmon K, Renouf D, Chia S, Bosdet I, Rassekh SR, Deyell RJ, Yip S, Fisic A, Titmuss E, Abadi S, Jones SJM, Sun S, Karsan A, Marra M, Laskin J, Lim H, Schrader KA.
    • JNCI Cancer Spectr. 2020 May 29; pkaa045. doi: 10.1093/jncics/pkaa045. eCollection 2020 May.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
    • He G, Xie X, Siddik ZH.
    • Cancer Chemother Pharmacol. 2020 May 28. doi: 10.1007/s00280-020-04085-1. Epub ahead of print.
    • Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    • Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1623. Epub ahead of print.
    • Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    • Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1626. Epub ahead of print.
    • High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    • Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Mol Biol Rep. 2020 May 28. doi: 10.1007/s11033-020-05504-5. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges.
    • Lee JS, Yost SE, Yuan Y.
    • Cancers (Basel). 2020 May 29;12(6):E1404. doi: 10.3390/cancers12061404.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
    • He G, Xie X, Siddik ZH.
    • Cancer Chemother Pharmacol. 2020 May 28. doi: 10.1007/s00280-020-04085-1. Epub ahead of print.
    • Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
    • Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1623. Epub ahead of print.
    • Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    • Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD.
    • J Clin Pharmacol. 2020 May 28. doi: 10.1002/jcph.1626. Epub ahead of print.
    • High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    • Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Mol Biol Rep. 2020 May 28. doi: 10.1007/s11033-020-05504-5. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Germline Insights from NGS Somatic Testing: Clinical Challenges and Controversies.
    • Matloff ET, Giri VN, Nowak JA, Sotelo J, Silver DP.
    • Precision Oncology News. Resources: Webinars. 2020 Jun 1.
    • Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
    • Alhopuro P, Vainionpää R, Anttonen AK, Aittomäki K, Nevanlinna H, Pöyhönen M.
    • Fam Cancer. 2020 May 28. doi: 10.1007/s10689-020-00186-1. [Epub ahead of print]
    • Genetic Testing Challenges in Oncology: Missed Mutations Highlight Somatic, Germline Test Difference.
    • Ray T.
    • Precision Oncology News. 2020 May 26.
    • Biomarker-Guided Development of DNA Repair Inhibitors.
    • Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD.
    • Mol Cell. 2020 May 17:S1097-2765(20)30277-X. doi: 10.1016/j.molcel.2020.04.035. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
    • Nishikawa G, Booth C, Prasad V.
    • Cancer. 2020 May 27. doi: 10.1002/cncr.32979. [Epub ahead of print]
    • Commentary
    • PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
    • Gonçalves A, Bertucci A, Bertucci F.
    • Cancers (Basel). 2020 May 27;12(65):E1378. doi: 10.3390/cancers12061378.
    • Wise Management of Ovarian Cancer: On the Cutting Edge.
    • Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • J Pers Med. 2020 May 21;10(2):E41. doi: 10.3390/jpm10020041.
    • Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
    • Vikas P, Borcherding N, Chennamadhavuni A, Garje R.
    • Front Oncol. 2020 Apr 28;10:570. doi: 10.3389/fonc.2020.00570.
  • LitAlert ~~ GeneLit.com

    • Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report.
    • Favier L, Truc G, Boidot R, Bengrine-Lefevre L.
    • Mol Clin Oncol. 2020 Jul;13(1):73-75. doi: 10.3892/mco.2020.2035. Epub 2020 Apr 27.
    • Integrating Genetic and Genomic Testing Into Oncology Practice.
    • Domchek SM, Mardis E, Carlisle JW, Owonikoko TK.
    • Am Soc Clin Oncol Educ Book. 2020 May;40:e259-e263. doi: 10.1200/EDBK_280607.
  • LitAlert ~~ GeneLit.com

    • Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
    • Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B.
    • Oncologist. 2020 May 26. doi: 10.1634/theoncologist.2020-0039. Epub ahead of print.
    • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    • Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN.
    • Pharmacol Ther. 2020 May 22:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub ahead of print.
    • Review
    • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    • Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN.
    • Pharmacol Ther. 2020 May 22:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer – a potential management strategy in the era of COVID-19.
    • Vetter MH, Smrz SA, Copeland LJ, Cohn DE.
    • Am J Obstet Gynecol. 2020 May 23. pii: S0002-9378(20)30569-X. doi: 10.1016/j.ajog.2020.05.037. [Epub ahead of print]
    • New OS Data With Olaparib Support 'New Era' for Ovarian Cancer.
    • Davenport L.
    • Medscape. 2020 May 14.